Impact of Inhaled Tobramycin on Healthcare Utilization and Morbidity in Non-CF Pediatric Tracheostomy Dependent Patients with Pseudomonas Infections
Introduction: Tracheostomy-dependent pediatric patients face an increased risk of respiratory infections due to bacterial colonization by Pseudomonas aeruginosa (PA). Inhaled antibiotics, such as tobramycin, were developed as targeted treatments to reduce infection rates and the need for systemic antibiotics; however, limited research explores their use in tracheostomy-dependent children, particularly their impact on healthcare utilization and optimal dosing. Methods: We conducted a retrospective cohort study at Children’s National Hospital in Washington, DC, including tracheostomy-dependent patients aged 0 to 21 years from January 1, 2003, to June 30, 2023. Patients with cystic fibrosis (CF), bronchiectasis, or primary ciliary dyskinesia were excluded. The primary outcome measured emergency department visits, regular floor admissions, ICU admissions, and systemic antibiotic use six months before and after initiating inhaled tobramycin. The secondary outcome assessed changes in PA positivity rates. Results: A total of 42 children were included, with a median age of 2 years; 64.3% were male. Neurologic disorders (45.2%) and bronchopulmonary dysplasia (26.2%) were the most common reasons for tracheostomy. Inhaled tobramycin therapy was associated with reduced regular admissions (p = 0.04), ICU admissions (p = 0.006), and systemic antibiotic use (p = 0.05). PA positivity decreased from 40.5% to 30.9% post-treatment (p = 0.001). Conclusion: This study the largest in non-CF, tracheostomy-dependent children demonstrates that inhaled tobramycin significantly reduces hospitalizations, ICU admissions, and antibiotic use. Although 40% of patients received doses between 160 mg and 300 mg every other month, dose variability did not significantly impact clinical outcomes.
Read more